title: Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
abstract: Using the intramolecular 5-exo-5-hexenyl radical as a key cyclization step, we previously reported an unambiguous synthesis of carba-LNA thymine (cLNA-T), which we subsequently incorporated in antisense oligonucleotides (AON) and investigated their biochemical properties [J. Am. Chem. Soc.2007, 129 (26), 8362-8379]. These cLNA-T incorporated oligos showed specific RNA affinity of +3.5-5 °C/modification for AON:RNA heteroduplexes, which is comparable to what is found for those of LNAs (Locked Nucleic Acids). These modified oligos however showed significantly enhanced nuclease stability (ca. 100 times more) in the blood serum compared to those of the LNA modified counterparts without compromising any RNase H recruitment capability. We herein report the synthesis of 5-methylcytosine-1-yl ((Me)C), 9-adeninyl (A), and 9-guaninyl (G) derivatives of cLNA and their oligonucleotides and report their biochemical properties as potential RNA-directed inhibitors. In a series of isosequential carba-LNA modified AONs, we herein show that all the cLNA modified AONs are found to be RNA-selective, but the magnitude of RNA-selectivity of 7'-R-Me-cLNA-G (cLNA-G) (ΔT(m) = 2.9 °C/modification) and intractable isomeric mixtures of 7'-(S/R)-Me-cLNA-T (cLNA-T, ΔT(m) = 2.2 °C/modification) was found to be better than diastereomeric mixtures of 7'-(S/R)-Me-cLNA-(Me)C with trace of cENA-(Me)C (cLNA-(Me)C, ΔT(m) = 1.8 °C/modification) and 7'-R-Me-cLNA-A (cLNA-A, ΔT(m) = 0.9 °C/modification). cLNA-(Me)C modified AONs however exhibited the best nuclease stability, which is 4-, 7-, and 20-fold better, respectively, than cLNA-T, cLNA-A, and cLNA-G modified counterparts, which in turn was more than 100 times stable than that of the native. When the modification sites are appropriately chosen in the AONs, the cLNA-A, -G, and -(Me)C modified sites in the AON:RNA hybrids can be easily recognized by RNase H, and the RNA strand of the hybrid is degraded in a specific manner, which is important for the design of oligos for therapeutic purposes. The cLNA-(Me)C modified AON/RNA, however, has been found to be degraded 4 times faster than cLNA-A and G modified counterparts. By appropriately choosing the carba-LNA modification sites in AON strands, the digestion of AON:RNA can be either totally repressed or be limited to cleavage at specific sites or at a single site only (similar to that of catalytic RNAzyme or DNAzyme). Considering all physico- and biochemical aspects of cLNA modified oligos, the work suggests that the cLNA modified antisense oligos have the potential of being a promising therapeutic candidate due to their (i) higher nucleobase-specific RNA affinity and RNA selectivity, (ii) greatly improved nuclease stability, and (iii) efficient RNase H recruitment capability, which can induce target RNA cleavage in a very specific manner at multiple or at a single site, in a designed manner.
authors.affiliation: Institute of Molecular Medicine, International Biotech Park, Tal Mulshi, Hinjewadi, Pune, India.
authors.forename: RamShankar
authors.initials: R
authors.lastname: Upadhayaya
authors.forename: Sachin Gangadhar
authors.initials: SG
authors.lastname: Deshpande
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.forename: Ramakant Asaram
authors.initials: RA
authors.lastname: Kardile
authors.forename: Aftab Yusuf
authors.initials: AY
authors.lastname: Sayyed
authors.forename: Eknath Kamalakar
authors.initials: EK
authors.lastname: Kshirsagar
authors.forename: Rahul Vilas
authors.initials: RV
authors.lastname: Salunke
authors.forename: Shailesh Satish
authors.initials: SS
authors.lastname: Dixit
authors.forename: Chuanzheng
authors.initials: C
authors.lastname: Zhou
authors.forename: András
authors.initials: A
authors.lastname: Földesi
authors.forename: Jyoti
authors.initials: J
authors.lastname: Chattopadhyaya
mesh_terms: D001483:Base Sequence; D003500:Cyclization; D004795:Enzyme Stability; D004926:Escherichia coli / Q000201:enzymology; D005092:Exonucleases / Q000378:metabolism*; D006801:Humans; D008958:Models, Molecular; D008968:Molecular Conformation; D009691:Nucleic Acid Denaturation; D009693:Nucleic Acid Hybridization; D009841:Oligonucleotides / Q000737:chemistry*; D016376:Oligonucleotides, Antisense / Q000097:blood / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D009943:Organophosphorus Compounds / Q000737:chemistry; D012313:RNA / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D016914:Ribonuclease H / Q000378:metabolism*; D013379:Substrate Specificity; D013816:Thermodynamics; D044366:Transition Temperature
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D009943:Organophosphorus Compounds; C477371:locked nucleic acid; C434331:phosphoramidite; D012313:RNA; D005092:Exonucleases; C022650:spleen exonuclease; D016914:Ribonuclease H